Use of antihypertensive medications in pregnancy and the risk of adverse perinatal outcomes: McMaster Outcome Study of Hypertension In Pregnancy 2 (MOS HIP 2)

Table 4 Rate and adjusted odds ratios (OR) for small for gestational age birthweight (SGA) and preterm birth among the offspring of women with any form of hypertension, according to type of antihypertensive therapy received during pregnancy

			Preterm birth
	SGA		Before 32 weeks		Before 37 weeks
Type of anti-hypertensive therapy	Rate (%)^*	Adjusted OR (95% CI)^**	Rate (%)	Adjusted OR (95% CI)	Rate (%)	Adjusted OR (95% CI)
None	9.0	1.0	1.9	1.0	12.2	1.0
β-blocker	19.9	2.3 (1.6–3.3)	14.7	7.6 (4.1–14.1)	45.3	5.1 (3.8–6.9)
Non-β-blocker	20.7	2.1 (1.3–3.4)	20.7	13.4 (6.8–26.2)	62.2	10.3 (7.0–15.3)
Both β-blocker and non-β-blocker	28.5	2.7 (1.8–3.9)	34.7	21.1 (11.6–38.3)	87.5	41.2 (27.7–61.2)

^*Represents the rate for each perinatal outcome according to type of antihypertensive therapy ^**All odds ratios were adjusted for maternal age, parity, pre-pregnancy weight, history of delivery before 34 weeks, history of hypertension in a previous pregnancy, cigarette smoking, pre-pregnancy diabetes mellitus, pre-pregnancy renal dysfunction, use of prednisone, and gestational age at which blood pressure first increased above 140/90 mm Hg.

ISSN: 1471-2393